Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

BACKGROUND: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Ana, Salgado, Mercedes, García, Adelaida, Buxò, Elvira, Vera, Ruth, Adeva, Jorge, Jiménez-Fonseca, Paula, Quintero, Guillermo, Llorca, Cristina, Cañabate, Mamen, López, Luis Jesús, Muñoz, Andrés, Ramírez, Patricia, González, Paula, López, Carlos, Reboredo, Margarita, Gallardo, Elena, Sanchez-Cánovas, Manuel, Gallego, Javier, Guillén, Carmen, Ruiz-Miravet, Nuria, Navarro-Pérez, Víctor, De la Cámara, Juan, Alés-Díaz, Inmaculada, Pazo-Cid, Roberto Antonio, Carmona-Bayonas, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267080/
https://www.ncbi.nlm.nih.gov/pubmed/30497432
http://dx.doi.org/10.1186/s12885-018-5101-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267080/
https://www.ncbi.nlm.nih.gov/pubmed/30497432
http://dx.doi.org/10.1186/s12885-018-5101-3

Ejemplares similares